{‘She has no qualifications’: this American healthcare establishment braces for Dr. Høeg's role at the Food and Drug Administration.

As the United States continues making historic changes to its vaccine recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by casting doubt on COVID-19 shots throughout the pandemic and has focused upon possible fatalities after COVID-19 immunization in her short position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Schedule

Health officials planned to reveal major revisions to the childhood vaccination calendar in December, aligning the US with Denmark’s national calendar, it is understood – a significant shift that would put the US out of step with much of the world with little proof for benefit. The announcement has been delayed until the new year.

Instead of the top vaccines chief, Dr. Høeg is listed to present at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a strengthened alliance between the drug and biologics branches as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon reevaluating already-approved immunizations at the FDA.

Høeg has repeatedly called for ending certain pediatric immunization guidelines in the US so as to align more like the Danish model, a society with nationalized medicine and a number of inhabitants roughly the population of the state of Wisconsin.

So far statements, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Qualifications

The appointee has no apparent background in drug development, approval processes or leadership, which has been standard for past leaders of the biologics center. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a sizeable institution. She has no expertise in drug approvals.”

Former commissioners of the center would “understand regulatory frameworks and the science of medication creation”, said a former acting FDA commissioner. “Frankly, she lacks the sort of resume that prior appointees who headed the center have had.”

The drug center has an immense range of responsibilities at the FDA, Woodcock emphasized.

“Many people just focuses on the new drug program, but the generic program clears thousands of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and all of those need to be supervised,” Woodcock noted. “The thing you neglect, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a major management aspect to the role, which manages over 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” the former official added.

Official Statement and Controversial Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this selection signifies greater collaboration among agency officials on immunizations, a spokesperson responded that the “questions rely on incorrect premises”.

“This background aligns with the responsibilities of her role,” the official explained, citing the months Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's new fast-track approval initiative, a contentious expedited drug-approval program that apparently concerned her preceding directors. “By what process are these drugs being selected for this expedited pathway? Who is making the calls?” Howard asked. “There’s a lot of confidentiality happening at the agency right now.”

In general, he stated, “the Food and Drug Administration looks to be trending towards less stringent rules of pharmaceuticals, with the exception of vaccines.”

Documented History on Immunizations

Regarding immunizations, Dr. Høeg has a more documented, if troubling, past, critics said. She published a analysis using unverified volunteer-provided data to determine the frequency of myocarditis following COVID-19 immunization. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to suggest COVID-19 vaccinations are more dangerous than they are.

Part of her “policy goals” for the new federal leadership encompassed changing guidelines for novel immunizations and discontinuing “optional” immunizations, she stated after the election on a audio program. At the FDA, Dr. Høeg has reportedly suggested excluding teenage boys from getting COVID-19 vaccinations.

“She is an thorough ideologue who begins with her conclusions and works backwards to fit the evidence in a very deceptive, untruthful manner,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Høeg became part of other dissenters, {like|